{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T23:49:23Z","timestamp":1788306563539,"version":"build-2803163510"},"reference-count":60,"publisher":"Elsevier BV","issue":"47","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,8,6]],"date-time":"2020-08-06T00:00:00Z","timestamp":1596672000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.vaccine.2020.08.007","type":"journal-article","created":{"date-parts":[[2020,8,15]],"date-time":"2020-08-15T01:32:31Z","timestamp":1597455151000},"page":"7558-7568","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["Modelling the impact of 4CMenB and MenACWY meningococcal combined vaccination strategies including potential 4CMenB cross-protection: An application to England"],"prefix":"10.1016","volume":"38","author":[{"given":"Ekkehard","family":"Beck","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Klint","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Abbing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronique","family":"Abitbol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orjan","family":"Akerborg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6853-068X","authenticated-orcid":false,"given":"Lorenzo","family":"Argante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafik","family":"Bekkat-Berkani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cosmina","family":"Hogea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Neine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kumaran","family":"Vadivelu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Whelan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kinga","family":"Meszaros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2020.08.007_b0005","unstructured":"European Centre for Disease Prevention and Control (ECDC). Factsheet about meningococcal disease; 2019. https:\/\/ecdc.europa.eu\/en\/meningococcal-disease\/factsheet [accessed 23-09-2019]."},{"issue":"4","key":"10.1016\/j.vaccine.2020.08.007_b0010","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s40121-018-0213-2","article-title":"Systematic review of invasive meningococcal disease: sequelae and quality of life impact on patients and their caregivers","volume":"7","author":"Olbrich","year":"2018","journal-title":"Infect Dis Ther"},{"issue":"16","key":"10.1016\/j.vaccine.2020.08.007_b0015","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1016\/j.vaccine.2017.03.007","article-title":"The epidemiology of invasive meningococcal disease in EU\/EEA countries, 2004\u20132014","volume":"35","author":"Whittaker","year":"2017","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.vaccine.2020.08.007_b0020","first-page":"220","article-title":"Meningococcal serogroup C conjugate vaccination in England and Wales: coverage and initial impact of the campaign","volume":"5","author":"Trotter","year":"2002","journal-title":"Commun Dis Public Health"},{"issue":"5","key":"10.1016\/j.vaccine.2020.08.007_b0025","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1128\/CVI.00529-09","article-title":"Updated postlicensure surveillance of the meningococcal C conjugate vaccine in England and Wales: effectiveness, validation of serological correlates of protection, and modeling predictions of the duration of herd immunity","volume":"17","author":"Campbell","year":"2010","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2020.08.007_b0030","unstructured":"Public Health England (PHE). Invasive meningococcal disease (laboratory reports in England): 2014\/2015 annual data by epidemiological year. Infection report 2015;9(38). https:\/\/assets.publishing.service.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/498057\/hpr3815_imd-crrctd.pdf [accessed 11-07-2018]."},{"key":"10.1016\/j.vaccine.2020.08.007_b0035","unstructured":"Public Health England (PHE). Invasive meningococcal disease in England: annual laboratory confirmed reports for epidemiological year 2016 to 2017. Health Protection Report 2017;11(38) . https:\/\/assets.publishing.service.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/655626\/hrp3817_IMD.pdf [accessed 20-02-2020]"},{"key":"10.1016\/j.vaccine.2020.08.007_b0040","unstructured":"Public Health England (PHE). Invasive meningococcal disease (laboratory reports in England): 2013\/2014 annual data by epidemiological year. Infection report 2015;9(3). https:\/\/assets.publishing.service.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/397913\/hpr0315_imd.pdf [accessed 30-04-2020]."},{"key":"10.1016\/j.vaccine.2020.08.007_b0045","unstructured":"Public Health England (PHE). Invasive meningococcal disease in England: annual laboratory confirmed reports for epidemiological year 2018 to 2019. Health Protection Report 2019;13(38).. https:\/\/assets.publishing.service.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/842368\/hpr3819_IMD-ann.pdf [accessed 03-02-2020]."},{"key":"10.1016\/j.vaccine.2020.08.007_b0050","unstructured":"European Medicines Agency (EMA). Bexsero Summary of Product Characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/bexsero-epar-product-information_en.pdf [accessed 21-07-2020]."},{"key":"10.1016\/j.vaccine.2020.08.007_b0055","unstructured":"European Centre for Disease Prevention and Control (ECDC). Invasive meningococcal disease - Annual Epidemiological Report for 2015. Stockholm: ECDC; 2017. https:\/\/ecdc.europa.eu\/sites\/portal\/files\/documents\/AER_for_2015-meningococcal-disease.pdf [accessed 11-06-2018]."},{"key":"10.1016\/j.vaccine.2020.08.007_b0060","unstructured":"European Centre for Disease Prevention and Control (ECDC). Invasive meningococcal disease - Annual Epidemiological Report for 2017. Stockholm: ECDC; 2019. https:\/\/www.ecdc.europa.eu\/sites\/default\/files\/documents\/AER_for_2017-invasive-meningococcal-disease.pdf [accessed 2-12-2019]."},{"key":"10.1016\/j.vaccine.2020.08.007_b0065","unstructured":"European Centre for Disease Prevention and Control (ECDC). Invasive meningococcal disease. Annual Epidemiological Report for 201. Stockholm: ECDC; 2018. https:\/\/www.ecdc.europa.eu\/sites\/default\/files\/documents\/AER_for_2016-invasive-meningococcal-disease_1.pdf [accessed 21-02-2020]."},{"issue":"9","key":"10.1016\/j.vaccine.2020.08.007_b0070","doi-asserted-by":"crossref","first-page":"382","DOI":"10.5694\/mja16.01340","article-title":"Epidemiology of invasive meningococcal B disease in Australia, 1999\u20132015: priority populations for vaccination","volume":"207","author":"Archer","year":"2017","journal-title":"Med J Aust"},{"key":"10.1016\/j.vaccine.2020.08.007_b0075","unstructured":"Health Service Executive NIAC recommendations - Meningococcal infection; 2016. https:\/\/www.hse.ie\/eng\/health\/immunisation\/hcpinfo\/guidelines\/chapter13.pdf [accessed 19-06-2018]."},{"key":"10.1016\/j.vaccine.2020.08.007_b0080","unstructured":"Health Service Executive (HSE). Immunisation Schedule (Ireland); 2020. https:\/\/www.hse.ie\/eng\/health\/immunisation\/pubinfo\/pcischedule\/immschedule\/ [accessed 21-02-2020]."},{"key":"10.1016\/j.vaccine.2020.08.007_b0085","unstructured":"Government of Italy. Piano Nazionale Prevenzione Vaccinale 2017-2019; 2017. http:\/\/www.salute.gov.it\/imgs\/C_17_pubblicazioni_2571_allegato.pdf [accessed 19-06-2018]."},{"key":"10.1016\/j.vaccine.2020.08.007_b0090","unstructured":"Istituto per la Sicurezza Sociale (ISS). Calendario vaccinale (Pediatriche); 2019. http:\/\/www.iss.sm\/on-line\/home\/vaccini-e-vaccinazioni\/vaccinazioni-raccomandate.html [accessed 2-12-2019]."},{"key":"10.1016\/j.vaccine.2020.08.007_b0095","unstructured":"Ministry of Health (Lithuania). Approval of pediatric vaccination calendar (D\u0117l Lietuvos Respublikos Vaik\u0173 Profilaktini\u0173 Skiepijim\u0173 Kalendoriaus Patvirtinimo); 2018. https:\/\/www.e-tar.lt\/portal\/lt\/legalAct\/333a8c10ab9211e88f64a5ecc703f89b [accessed 21-02-2020]."},{"key":"10.1016\/j.vaccine.2020.08.007_b0100","unstructured":"Ministry of Health (Lithuania). Amendment V-757 Pediatric vaccination calendar (2015 M. Bir\u017eelio 12 D. \u012esakymo Nr. V-757, D\u0117l Lietuvos Respublikos Vaik\u0173 Profilaktini\u0173 Skiepijim\u0173 Kalendoriaus Patvirtinimo\u201c Pakeitimo); 2015. https:\/\/e-seimas.lrs.lt\/portal\/legalAct\/lt\/TAD\/f4a925d0f50f11e79a1bc86190c2f01a?positionInSearchResults=0&searchModelUUID=1561434a-b283-4be2-87f5-4f556ad37c32 [accessed 21-02-2020]."},{"key":"10.1016\/j.vaccine.2020.08.007_b0105","unstructured":"Govern d'Andorra - Ministeri de Salut. Recomanacions sobre l\u2019administraci\u00f3 de la vacunaci\u00f3 enfront del Meningococ B (Bexsero); 2016. https:\/\/www.salut.ad\/images\/stories\/Salut\/pdfs\/temes_salut\/Recomanacions_Vacuna_Bexero.pdf [accessed 2-12-2019]."},{"key":"10.1016\/j.vaccine.2020.08.007_b0110","unstructured":"Govern d'Andorra - Ministeri de Salut. Calendari de vacunacions; 2016. https:\/\/www.salut.ad\/images\/stories\/Salut\/pdfs\/temes_salut\/Calendari_vacunacions.pdf [accessed 2-12-2019]."},{"key":"10.1016\/j.vaccine.2020.08.007_b0115","unstructured":"El Pais. Bexsero: Castilla y Le\u00f3n joins the Canary Islands and will finance B Meningitis vaccine; 2019. https:\/\/elpais.com\/elpais\/2019\/02\/20\/mamas_papas\/1550651257_475679.html [accessed 2-12-2019]."},{"key":"10.1016\/j.vaccine.2020.08.007_b0120","unstructured":"Government of South Australia. Meningococcal B Immunisation Program; 2019. https:\/\/www.sahealth.sa.gov.au\/wps\/wcm\/connect\/public+content\/sa+health+internet\/conditions\/immunisation\/immunisation+programs\/meningococcal+b+immunisation+program. [accessed 08-08-2020]."},{"key":"10.1016\/j.vaccine.2020.08.007_b0125","unstructured":"Government of Portugal - Gabinete do Secret\u00e1rio de Estado da Sa\u00fade. Despacho n.\u00b0 12434\/2019; 2019. https:\/\/dre.pt\/application\/conteudo\/127608823 [accessed 27-03-2020]."},{"issue":"4","key":"10.1016\/j.vaccine.2020.08.007_b0130","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1056\/NEJMoa1901229","article-title":"Vaccination of Infants with Meningococcal Group B Vaccine (4CMenB) in England","volume":"382","author":"Ladhani","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2020.08.007_b0135","unstructured":"Pizza M, Biolchi A, De Angelis G, et al. Abstract ESPID19-0255: A Multicomponent Meningococcal Serogroup B Vaccine Developed for Serogroup B Meningococci Elicits Cross-Reactive Immunity Against Serogroups C, W and Y. European Society for Paediatric Infectious Diseases, 37th Annual Meeting; 2019."},{"key":"10.1016\/j.vaccine.2020.08.007_b0140","unstructured":"Biolchi A, Giuliani M, Tomei S, et al. Multicomponent meningococcal serogroup B vaccine (4CMenB) may elicit functional immunity against serogroup A strains. Meningitis Research Foundation - 2019 International Conference Meningitis and Septicaemia 2019; 2019."},{"issue":"7","key":"10.1016\/j.vaccine.2020.08.007_b0145","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.3201\/eid2307.170236","article-title":"Emergency meningococcal ACWY vaccination program for teenagers to control croup W meningococcal disease, England, 2015\u20132016","volume":"23","author":"Campbell","year":"2017","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.vaccine.2020.08.007_b0150","unstructured":"S Ladhani. Increase in group W meningococcal disease in the UK. In: 15th European Meningococcal and Haemophilus Disease Society (EMGM) Congress 2019; Lisbon, Portugal."},{"key":"10.1016\/j.vaccine.2020.08.007_b0155","unstructured":"GSK. Menveo Prescribing Information; 2020. https:\/\/gsksource.com\/pharma\/content\/dam\/GlaxoSmithKline\/US\/en\/Prescribing_Information\/Menveo\/pdf\/MENVEO.PDF [accessed 27-03-2020]."},{"key":"10.1016\/j.vaccine.2020.08.007_b0160","unstructured":"European Medicines Agency (EMA). Nimenrix Summary of Product Characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/nimenrix-epar-product-information_en.pdf [accessed 27-03-2020]."},{"issue":"9960","key":"10.1016\/j.vaccine.2020.08.007_b0165","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1016\/S0140-6736(14)60842-4","article-title":"Effect of a quadrivalent meningococcal ACWY glycoconjugate or a serogroup B meningococcal vaccine on meningococcal carriage: an observer-blind, phase 3 randomised clinical trial","volume":"384","author":"Read","year":"2014","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.vaccine.2020.08.007_b0170","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1056\/NEJMoa1900236","article-title":"Meningococcal B Vaccine and Meningococcal Carriage in Adolescents in Australia","volume":"382","author":"Marshall","year":"2020","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1016\/j.vaccine.2020.08.007_b0175","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1016\/j.vaccine.2013.03.034","article-title":"Introducing vaccination against serogroup B meningococcal disease: an economic and mathematical modelling study of potential impact","volume":"31","author":"Christensen","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.08.007_b0180","article-title":"Re-evaluating cost effectiveness of universal meningitis vaccination (Bexsero) in England: modelling study","volume":"349","author":"Christensen","year":"2014","journal-title":"BMJ Open"},{"issue":"29","key":"10.1016\/j.vaccine.2020.08.007_b0185","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1016\/j.vaccine.2016.04.004","article-title":"Epidemiological impact and cost-effectiveness of universal vaccination with Bexsero(\u00ae) to reduce meningococcal group B disease in Germany","volume":"34","author":"Christensen","year":"2016","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2020.08.007_b0190","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.vaccine.2016.11.076","article-title":"Modelling the cost-effectiveness of catch-up 'MenB' (Bexsero) vaccination in England","volume":"35","author":"Christensen","year":"2017","journal-title":"Vaccine"},{"issue":"9","key":"10.1016\/j.vaccine.2020.08.007_b0195","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1017\/S095026881300294X","article-title":"Modelled evaluation of multi-component meningococcal vaccine (Bexsero\u00ae) for the prevention of invasive meningococcal disease in infants and adolescents in the UK","volume":"142","author":"Huels","year":"2014","journal-title":"Epidemiol Infect"},{"key":"10.1016\/j.vaccine.2020.08.007_b0200","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s12916-016-0642-2","article-title":"Fast and accurate dynamic estimation of field effectiveness of meningococcal vaccines","volume":"14","author":"Argante","year":"2016","journal-title":"BMC Med"},{"issue":"1","key":"10.1016\/j.vaccine.2020.08.007_b0205","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1093\/aje\/kwi160","article-title":"Dynamic models of meningococcal carriage, disease, and the impact of serogroup C conjugate vaccination","volume":"162","author":"Trotter","year":"2005","journal-title":"Am J Epidemiol"},{"issue":"1","key":"10.1016\/j.vaccine.2020.08.007_b0210","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1177\/0272989X05284109","article-title":"Reassessing the cost-effectiveness of meningococcal serogroup C conjugate (MCC) vaccines using a transmission dynamic model","volume":"26","author":"Trotter","year":"2006","journal-title":"Med Decis Making"},{"issue":"3","key":"10.1016\/j.vaccine.2020.08.007_b0215","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1017\/S0950268805005339","article-title":"The natural history of meningococcal carriage and disease","volume":"134","author":"Trotter","year":"2006","journal-title":"Epidemiol Infect"},{"issue":"1","key":"10.1016\/j.vaccine.2020.08.007_b0220","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.vaccine.2013.09.034","article-title":"Evaluation of serogroup C and ACWY meningococcal vaccine programs: projected impact on disease burden according to a stochastic two-strain dynamic model","volume":"33","author":"Vickers","year":"2015","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2020.08.007_b0225","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1080\/21645515.2015.1080400","article-title":"Exploring the population-level impact of MenB vaccination via modeling: Potential for serogroup replacement","volume":"12","author":"Hogea","year":"2016","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2020.08.007_b0230","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1186\/s12879-015-1015-8","article-title":"The impact of aggregating serogroups in dynamic models of Neisseria meningitidis transmission","volume":"15","author":"Poore","year":"2015","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.vaccine.2020.08.007_b0235","unstructured":"Rodrigues F. Portuguese Meningococcus Group B Vaccine Effectiveness Study (PT-BEST) - preliminary results. 15th European Meningococcal and Haemophilus Disease Society (EMGM) Congress; 2019; Lisbon, Portugal."},{"key":"10.1016\/j.vaccine.2020.08.007_b0240","unstructured":"Centers for Disease Control and Prevention (CDC) - McNamara L.A., BlainA. Manual for the Surveillance of Vaccine-Preventable Diseases. Chapter 8 Meningococcal; 2019. https:\/\/www.cdc.gov\/vaccines\/pubs\/surv-manual\/chpt08-mening.html [accessed 21-02-2020]."},{"issue":"12","key":"10.1016\/j.vaccine.2020.08.007_b0245","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/S1473-3099(10)70251-6","article-title":"Meningococcal carriage by age: a systematic review and meta-analysis","volume":"10","author":"Christensen","year":"2010","journal-title":"Lancet Infect Dis"},{"issue":"4","key":"10.1016\/j.vaccine.2020.08.007_b0250","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-024343","article-title":"Serogroup-specific meningococcal carriage by age group: a systematic review and meta-analysis","volume":"9","author":"Peterson","year":"2019","journal-title":"BMJ Open"},{"issue":"8","key":"10.1016\/j.vaccine.2020.08.007_b0255","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1093\/cid\/cix091","article-title":"Meningococcal carriage evaluation in response to a Serogroup B meningococcal disease outbreak and mass vaccination campaign at a College-Rhode Island, 2015\u20132016","volume":"64","author":"Soeters","year":"2017","journal-title":"Clin Infect Dis"},{"issue":"3","key":"10.1016\/j.vaccine.2020.08.007_b0260","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.0050074","article-title":"Social contacts and mixing patterns relevant to the spread of infectious diseases","volume":"5","author":"Mossong","year":"2008","journal-title":"PLoS Med"},{"issue":"2","key":"10.1016\/j.vaccine.2020.08.007_b0265","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1111\/j.1467-9876.2009.00693.x","article-title":"Estimating infectious disease parameters from data on social contacts and serological status","volume":"59","author":"Goeyvaerts","year":"2010","journal-title":"J R Stat Soc: Series C (Applied Statistics)"},{"key":"10.1016\/j.vaccine.2020.08.007_b0270","unstructured":"Public Health England (PHE) Invasive meningococcal infections laboratory reports in England by capsular group, age group & calendar year, 2000-2014 2015. https:\/\/web.archive.org\/web\/20151013112030\/https:\/\/www.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/432895\/Table_9_Invasive_meningococcal_infections_lab_reports__England_by_capsular_group___age.pdf [accessed 30-04-2020]."},{"issue":"2","key":"10.1016\/j.vaccine.2020.08.007_b0275","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2016-2193","article-title":"Effectiveness and duration of protection of one dose of a meningococcal conjugate vaccine","volume":"139","author":"Cohn","year":"2017","journal-title":"Pediatrics"},{"key":"10.1016\/j.vaccine.2020.08.007_b0280","doi-asserted-by":"crossref","unstructured":"ISRCTN registry Be on the TEAM: Teenagers Against Meningitis 2020. https:\/\/doi.org\/10.1186\/ISRCTN75858406 [accessed 21-02-2020].","DOI":"10.1186\/ISRCTN75858406"},{"issue":"8","key":"10.1016\/j.vaccine.2020.08.007_b0285","doi-asserted-by":"crossref","DOI":"10.1016\/j.cmi.2017.02.008","article-title":"Meningococcal carriage in Dutch adolescents and young adults; a cross-sectional and longitudinal cohort study","volume":"23","author":"van Ravenhorst","year":"2017","journal-title":"Clin Microbiol Infect"},{"issue":"3","key":"10.1016\/j.vaccine.2020.08.007_b0290","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.jinf.2017.12.005","article-title":"Antibody persistence and booster responses 24\u201336 months after different 4CMenB vaccination schedules in infants and children: a randomised trial","volume":"76","author":"Martinon-Torres","year":"2018","journal-title":"J Infect"},{"issue":"11","key":"10.1016\/j.vaccine.2020.08.007_bib291","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1097\/INF.0000000000000438","article-title":"Antibody persistence after primary and booster doses of a quadrivalent meningococcal conjugate vaccine in adolescents.","volume":"33","author":"Baxter","year":"2014","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2020.08.007_bib293","unstructured":"Public Health England (PHE). Vaccine coverage estimates for the school based meningococcal ACWY (MenACWY) adolescent vaccination programme in England, to 31 August 2018; 2019. https:\/\/assets.publishing.service.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/773539\/hpr0319_vc-menACWY.pdf. [accessed 10-08-2020]"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X20310288?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X20310288?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:49:23Z","timestamp":1759402163000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X20310288"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":60,"journal-issue":{"issue":"47","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["S0264410X20310288"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2020.08.007","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Modelling the impact of 4CMenB and MenACWY meningococcal combined vaccination strategies including potential 4CMenB cross-protection: An application to England","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2020.08.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 GlaxoSmithKlineBiologicals SA. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}